• Save 15%
search

DAFLON 60CPR RIV 500MG

  • SERVIER ITALIA SpA
  • 023356049
Final Price €22.95
Regular Price €27.00
Save 15%
Quantity
check_circle Available (12 Items)
48h
  Convenient and safe payments

Even with a credit card

  Shipping in 48h-72h all over the world

FREE in Italy over € 39.90

  Fast returns and 14 days to reconsider

14 days to reconsider

  90 years of pharmaceutical experience at your service

Always at your service

Drugs Others products at unbeatable price

SERVIER ITALIA SpA

Discover all products

DAFLON 60CPR RIV 500MG

Therapeutic indications

Symptoms attributable to venous insufficiency; states of capillary fragility.

Dosage and method of use

2 film-coated tablets per day (1 at noon and 1 in the evening) at mealtimes, even in venous insufficiency of the haemorrhoidal plexus.

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Side effects

The following adverse effects or reactions have been reported and ranked under the following frequency: very common (≥1 / 10); common (≥1 / 100, Nervous system disorders. Rare: dizziness, headache, malaise. Gastrointestinal disorders. Common: diarrhea, dyspepsia, nausea, vomiting; Uncommon: colitis; Not known: abdominal pain. Skin and subcutaneous tissue disorders. Rare: rash, itching, hives; Not known: edema of the face, lips, eyelid; Quincke's edema. Disorders of the blood and lymphatic system. Not known: thrombocytopenia. Reporting of suspected adverse reactions. Reporting of suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

Special warnings

None.

Pregnancy and breastfeeding

Pregnancy: Data on the use of purified micronized flavonoic fraction in pregnant women do not exist or are limited in number. Animal studies do not indicate reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Daflon during pregnancy. Feeding time: It is not known whether the active substance / metabolites are excreted in human milk. A risk to the newborns / infants cannot be excluded A decision must be made whether to discontinue breast-feeding or to discontinue / abstain from Daflon therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for women. Fertility: Reproductive toxicity studies did not show effects on fertility in either male or female rats (see section 5.3).

Expiry and retention

This medicinal product does not require any special storage conditions.

Interactions with other drugs

No interaction studies have been performed. To date, no clinically relevant drug interactions have been reported from post marketing experience on the product.

Overdose

Symptoms There is limited experience with Daflon overdose. The most frequently reported adverse events in overdose cases were gastrointestinal events (such as diarrhea, nausea, abdominal pain) and skin events (such as pruritus, rash). Management Management of overdose should consist of treatment of clinical symptoms.

Active principles

Each film-coated tablet contains 500 mg of purified micronized flavonoic fraction consisting of 450 mg of diosmin and 50 mg of flavonoids expressed in hesperidin. For the full list of excipients, see section 6.1.

Excipients

Sodium carboxymethyl starch, microcrystalline cellulose, gelatin, glycerin, hypromellose, sodium lauryl sulfate, yellow iron oxide E172, red iron oxide E 172, titanium dioxide, macrogol 6000, magnesium stearate, talc.

023356049
12 Items